Progress is not occurring quickly enough to meet the UN target
Over three decades, the world's encounter with cancer has grown from a serious challenge into a defining crisis of global health equity. A landmark study in The Lancet traces the disease's doubling from 9 million diagnoses in 1990 to 18.5 million in 2023, with projections reaching 30.5 million by 2050 — a trajectory shaped as much by inequality as by biology. Wealthier nations have learned to soften cancer's blow through screening and treatment, while lower-income countries face rising rates without the systems to respond, revealing that the future of this disease will be written not only in laboratories but in the choices societies make about who deserves care.
- Cancer diagnoses have doubled in a single generation and are on course to double again by 2050, driven by aging populations and entrenched risk factors that no country has fully conquered.
- The crisis is splitting along economic lines — wealthy nations have cut mortality rates by nearly a third while low- and middle-income countries watch their numbers climb with healthcare systems ill-equipped to absorb the pressure.
- A quiet alarm is sounding among younger populations: 14 cancer types are rising in Americans under 50, with early-onset cases often going undetected until the disease has advanced beyond easy reach.
- The world is measurably off course from UN targets to reduce premature cancer deaths by a third before 2030, and researchers warn that current momentum is nowhere near sufficient to close that gap.
- The path forward demands simultaneous action on prevention, screening, treatment access, and funding — a coordinated effort that no single nation has yet fully modeled, let alone exported to those who need it most.
A sweeping study published in The Lancet by researchers at the Institute for Health Metrics and Evaluation has confirmed what many in global health have feared: cancer is outpacing the world's ability to respond. Diagnoses climbed from 9 million in 1990 to 18.5 million in 2023, while deaths rose from 6 million to 10.4 million over the same period. By 2050, the projections reach 30.5 million new cases and 18.6 million deaths each year — a 60 percent increase driven largely by population growth and aging.
The numbers, however, do not fall evenly. The United States saw its age-standardized cancer incidence drop from 428 cases per 100,000 people in 1990 to 342 in 2023, with mortality falling by nearly a third. Those gains reflect sustained investment in screening, prevention, and treatment. But across low- and middle-income countries, rates are moving in the opposite direction, widening a global health equity gap that researchers describe as a two-tiered crisis. Even within the U.S., disparities persist — Maine's diagnosis rate of roughly 650 cases per 100,000 stands nearly double the national average.
The causes are familiar but resistant to easy solutions. Tobacco accounts for one in five cancer deaths worldwide. Air pollution, alcohol, poor diet, and elevated blood sugar compound the burden. A particularly unsettling pattern has emerged among younger Americans, where 14 cancer types — including breast, colorectal, and kidney — rose in incidence among people under 50 between 2010 and 2019, with many cases likely advancing undetected.
IHME's Lisa Force was direct about the stakes: the world is not moving fast enough to meet the UN's target of cutting premature deaths from non-communicable diseases by a third before 2030. Closing the gap, she argued, will require health systems that span the full arc from prevention to survivorship, aggressive reduction of known risk factors, expanded surveillance, and a genuine commitment to ensuring that quality care reaches every population — not only those with the means to seek it.
The world is getting sicker with cancer, and the trend is accelerating. A major study published in The Lancet found that global cancer diagnoses more than doubled over three decades, climbing from 9 million cases in 1990 to 18.5 million in 2023. Deaths from the disease rose in parallel, from around 6 million to 10.4 million. By 2050, researchers project those numbers will climb further still—to 30.5 million cases and 18.6 million deaths annually. The increase represents a 60 percent rise over the next quarter century, driven primarily by population growth and the aging of the global population.
The research, led by the Institute for Health Metrics and Evaluation at the University of Washington, paints a portrait of a disease burden that is reshaping global health priorities. Yet the story is not uniform. Wealthier nations have managed to bend the curve. In the United States, for instance, the age-standardized cancer incidence rate fell from 428 cases per 100,000 people in 1990 to 342 in 2023. Mortality dropped even more sharply—by nearly a third, from 169 deaths per 100,000 to 114. These gains reflect decades of investment in screening, treatment, and prevention. But the same progress has not reached much of the world. Low- and middle-income countries are experiencing rising rates even as their healthcare systems struggle to respond. The gap between rich and poor nations is widening, creating what amounts to a two-tiered cancer crisis.
Within the United States itself, geography matters enormously. Maine reports the highest cancer diagnosis rate in the country, with around 650 cases per 100,000 people in 2021—nearly double the national average. These disparities hint at deeper inequities in screening access, lifestyle factors, and healthcare quality that vary dramatically by region and population.
The drivers of rising cancer incidence are well understood but stubbornly persistent. Tobacco remains the leading preventable cause of cancer deaths globally, accounting for one in five. Air pollution, alcohol consumption, unhealthy diets, and high blood sugar levels all contribute significantly. A particularly troubling trend has emerged among younger Americans. Between 2010 and 2019, the incidence of 14 cancer types rose among people under 50, including breast, colorectal, kidney, and uterine cancers. Researchers worry these early-onset cases may be going undiagnosed because symptoms are dismissed or ignored until disease has advanced.
Lisa Force, an assistant professor at IHME, emphasized that the current trajectory falls short of global targets. "An awareness of the growing cancer burden is important so that healthcare systems can prepare for how best to meet the need," she told Newsweek. "This progress is not occurring quickly enough to meet the United Nations target of cutting premature deaths from non-communicable diseases, including cancer, by one third by 2030." The gap between where the world is and where it needs to be is substantial.
Reversing this trend will require sustained, multifaceted effort. Force outlined what that would look like: well-functioning health systems that span prevention and screening through treatment and survivorship care; aggressive reduction of known risk factors like tobacco, alcohol, air pollution, and poor diet; expanded cancer surveillance; increased funding; and ensuring that timely diagnosis and quality treatment reach all populations, not just the wealthy. Each country faces unique obstacles, she noted, but the fundamental requirements are universal. Without these interventions, the world will continue on its current path—toward a future in which cancer becomes an even larger burden on human health and healthcare budgets worldwide.
Citações Notáveis
An awareness of the growing cancer burden is important so that healthcare systems can prepare for how best to meet the need. This progress is not occurring quickly enough to meet the United Nations target of cutting premature deaths from non-communicable diseases, including cancer, by one third by 2030.— Lisa Force, assistant professor at the Institute for Health Metrics and Evaluation
A Conversa do Hearth Outra perspectiva sobre a história
Why has cancer incidence more than doubled since 1990 if we've made so much progress in treatment?
The doubling reflects two things happening at once. Yes, we've gotten better at treating cancer and preventing some deaths. But the global population has grown, and crucially, people are living longer. An older population naturally develops more cancer. So we're seeing both progress and a rising tide.
But if mortality rates have dropped in wealthy countries, why are cases still rising there?
Because incidence and mortality are different measures. You can have fewer people dying from cancer while more people are diagnosed with it—that's actually what's happening in places like the U.S. Better screening catches more cases early, when they're more treatable. That's progress. But it also means more diagnoses.
The study mentions early-onset cancers rising in people under 50. That seems different from the aging story.
It is. That's the unsettling part. We don't fully understand why breast, colorectal, and kidney cancers are rising in younger Americans. It could be lifestyle factors—diet, alcohol, obesity, sedentary behavior. It could be environmental. But researchers worry these cases are being missed because young people don't expect cancer and doctors don't screen for it.
Maine has twice the cancer rate of the national average. What explains that?
The study doesn't say, but geography matters for screening access, healthcare quality, lifestyle factors, and population demographics. Maine is older than the national average. It may also have different screening practices or different prevalence of risk factors.
The UN target is to cut premature deaths by a third by 2030. How far off are we?
Far enough that researchers are sounding the alarm. Current progress is real but uneven and too slow. Without accelerating prevention, screening, and treatment—especially in low- and middle-income countries—we won't hit that target.
What's the most actionable thing a country could do right now?
Probably tobacco control. It's the leading preventable cause of cancer deaths globally. After that, expanding screening and treatment access. But it requires sustained funding and political will, which is harder to come by than the knowledge of what to do.